Olumiant maintained a consistent safety profile in a long-term analysis of patients with rheumatoid arthritis
News
Updated guidelines for managing long-term effects of COVID-19 published
New guidelines from NICE, SIGN and the RCGP includes an update to original list of common symptoms
Valneva receives EU deal for COVID jab, and seeks apology from UK
Decision follows the UK government’s termination of their deal with Valneva in September
University of Oxford begins human trials of Ebola vaccine
ChAdOxl biEBOV is being tested for safety and immunogenicity, and may protect against multiple species of the virus
‘Ground-breaking’ research on inflammatory disease treatment set to be commercialised
The new research by Heriot-Watt University has identified a way of targeting an enzyme called EPAC1
SMC accepts oral therapy for relapsing multiple sclerosis
Janssen’s Ponvory accepted for use within NHS Scotland for adults RRMS patients
CN Bio inks COVID-19 research deal with iiCON
iiCON’s lead partner LSTM will independently validate CN Bio’s novel lung and lung-liver models
Sanofi invests $40m in UK gene therapy company Gyroscope Therapeutics
Funding proceeds will be used to support ongoing trials of Gyroscopes investigational gene therapy GT005
NHS staff face spring deadline for mandatory COVID vaccination
The government is expected to announce that frontline staff in England will have to be fully vaccinated against COVID-19
Positive results for GSK’s anaemia drug daprodustat
Daprodustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor in development for anaemia due to chronic kidney disease
Opdivo plus chemo improves event-free survival in NSCLC patients
Detailed results from the CheckMate-816 trial will be shared at an upcoming medical conference
AZ announces US fast track designation for IL-5 inhibitor Fasenra
Designation granted for the treatment of eosinophilic gastritis with or without eosinophilic gastroenteritis
UK gov’t warns of Christmas COVID restrictions, push for booster vaccines
Around 60% of those eligible have received their booster vaccinations in the UK
Pfizer’s COVID-19 pill cuts hospitalisation/death risk by 89%
The trial evaluated the investigational medicine in non-hospitalised adult patients with COVID-19 who are at high-risk of progressing to severe illness
Novartis’ iptacopan hits endpoints in mid-stage study
Investigational treatment is being evaluated in patients with C3 glomerulopathy
